Monte Rosa Therapeutics Cuts CRP by 85%, Eyes H2 2026 Phase 2 Trials
GLUE•Monte Rosa reported interim Phase 1 data showing MRT-8102 cut CRP levels by 85%, with 94% of high-CVD-risk subjects achieving sub-2 mg/L CRP, and plans to initiate three Phase 2 studies beginning H2 2026. The company holds $671 million in cash and equivalents, funding operations into 2029.
1. Financial Position
Monte Rosa ended Q1 with $671 million in cash, cash equivalents and marketable securities, providing a runway into 2029 without near-term financing needs.
2. MRT-8102 Clinical Progress
Interim data from the Phase 1 GFORCE-1 trial showed an 85% mean CRP reduction and 94% of participants achieving CRP below 2 mg/L after four weeks. The company anticipates a full GFORCE-1 readout in H2 2026 and will initiate three Phase 2 studies later this year in atherosclerotic risk, gout flares and hidradenitis suppurativa.
3. MRT-2359 Oncology Progress
Phase 1/2 results in mCRPC patients with AR mutations showed a 100% disease control rate in the AR-mutant cohort and 67% overall RECIST control across 15 evaluable patients. A Phase 2 trial combining MRT-2359 with apalutamide is planned for Q3 2026.
4. Collaboration and Preclinical Advances
The VAV1-directed MGD MRT-6160 is set for Novartis-led Phase 2 studies in immune-mediated diseases, with up to $2.1 billion in potential milestones. Preclinical cyclin E1-directed MGD data demonstrated superior selectivity, with an IND submission anticipated in H2 2026.
